Posted by Michael Wonder on 26 Jun 2017
AVEO Oncology announces positive CHMP opinion for tivozanib as a treatment of advanced renal cell carcinoma
23 June 2017 - AVEO Oncology today announced that the CHMP, the scientific committee of the EMA, has recommended Fotivda (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma.
The CHMP's recommendation is now referred to the European Commission (EC). The EC, which typically adheres to the recommendation of the CHMP, but is not obligated to do so, is expected to make its final decision in about 67 days. If approved by the EC, marketing authorisation for tivozanib will be granted in all 28 countries of the European Union, Norway, Iceland and Liechtenstein. EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, is the European licensee for tivozanib.
